HOME > 教室紹介 > 診療・研究内容 > (12)循環器EBM開発学講座

教室紹介

教室紹介

診療・研究内容

(12)循環器EBM開発学講座

近年の医療においては、根拠に基づく医療(Evdence-based Medicine、以下EBM)の実践が不可欠となっています。しかし、これまでわが国のEBMの基礎作りは欧米に比較して大きく立ち遅れていました。循環器EBM開発学寄附講座は、循環器疾患治療の日本人における数多くの科学的根拠(エビデンス、図1参照)を構築することを目的に、平成19年10月に開設しました。(循環器EBM開発学寄附講座
図1:科学的根拠のある医療図1:科学的根拠のある医療

現在進行中の主な研究テーマ

1. CHART-2研究とSUPPORT試験

図2・図3慢性心不全は全ての心血管疾患の最終像であり、その予後は不良であると考えられています。日本は世界でも有数の高齢化国家であり、高齢者に多い疾患である慢性心不全は今後爆発的に増加すると考えられています。我々は日本における慢性心不全の特徴や予後を明らかにすべく平成12年より慢性心不全の前向きコホート研究:東北慢性心不全登録(CHART-1研究)を開始し、多くの知見を発表してきました。これに引き続いて平成18年10月より東北地区の約20関連施設とともに東北心不全協議会を組織し、あらたなコホート研究:CHART-2研究(NCT00418041)を開始しました。このコホートは連続した心不全患者(ACC/AHAガイドラインのStage B〜D)1万例を登録し前向きに追跡するもので日本最大規模のコホート研究となります。

同時に、このコホートの中から、高血圧症を合併し症状のある慢性心不全患者1000人を対象にしてアンギオテンシンII受容体拮抗薬の追加によるイベント抑制効果を評価する臨床介入試験SUPPORT試験(NCT00417222)を開始しています。この試験により日本人における本薬剤の世界初のエビデンスが得られることが期待されます。本研究に興味をお持ちの方は、当科ホームページにアクセスして下さい

2. その他の現在進行中の研究

平成18年より2つの全国他施設共同研究、厚生労働省科研費研究「慢性心不全におけるメタボリック症候群の意義に関する研究」と「冠攣縮研究会」を開始しています。

図4:「慢性心不全におけるメタボリック症候群の意義に関する研究」のフロー図
図4:「慢性心不全におけるメタボリック症候群の意義に関する研究」のフロー図

図5:「冠攣縮研究会」ホームページ図5:「冠攣縮研究会」ホームページ

主な研究業績 (2004年以降)
2017年
  1. Oikawa T, Sakata Y, Nochioka K, Miura M, Tsuji K, Onose T, Abe R, Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H; the CHART-2 Investigators. Prognostic impact of statin intensity in heart failure patients with ischemic heart disease. A report from the CHART-2 study. JAHA. (in press) (IF=4.425)
  2. Ohyama K, Matsumoto Y, Takanami K, Ota H, Nishimiya K, Sugisawa J, Tsuchiya S, Amamizu H, Uzuka H, Suda A, Shindo T, Kikuchi Y, Hao K, Tsuburaya R, Takahashi J, Miyata S, Sakata Y, Takase K, Shimokawa H. Evidence for coronary adventitia and perivascular adipose tissue inflammation in patients with vasospastic angina. J Am Coll Cardiol. (in press) (IF=19.896)
  3. Nihei T, Takahashi T, Hao K, Kikuchi Y, Odaka Y, Tsuburaya R, Nishimiya K, Matsumoto Y, Ito K, Miyata S, Sakata Y, Shimokawa H. Prognostic impact of Rho-kinase activity in circulating leukocytes in patients with vasospastic angina. Eur Heart J. (in press) (IF=20.212)
  4. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, M, Glynn RJ; the CANTOS Trial Group. Anti-Inflammatory therapy with canakinumab for atherosclerotic disease. New Engl J Med. 377:1119-1131,2017.PDF
  5. Ong P, Camici PG, Beltrame J, Crea F, Shimokawa H, Sechtem U, Kaski JC, Merz CNB. International standardization of diagnostic criteria for microvascular angina. Int J Cardiol. (in press)
  6. Tokunaga H, Takahashi F, Yamamoto H, Honda T, Watanabe T, Shoji T, Sugiyama T, Yamada H, Tando T, Yoshinaga K, Kagabu S, Otsuki T, Kin S, Yokoyama Y, Wagatsuma S, Sato K, Sato H, Oishi T, Yoshida Y, Hayasaka T, Matsui T, Imai N, Nishigori H, Shimokawa H, Yaegashi N, Watanabe Y. Current status of uterine leiomyosarcoma in the Tohoku region: Results of the Tohoku Translational Center Development Network Survey. Int J Clin Oncol. 22:541-547,2017. (IF=3.079)PDF
  7. Onose T, Sakata Y, Nochioka K, Miura M, Yamauchi T, Tsuji K, Abe R, Oikawa T, Kasahara S, Sato M, Shiroto T, Miyata S, Takahashi J, Shimokawa H; the CHART-2 Investigators. Sex differences in post-traumatic stress disorder in cardiovascular patients after the Great East Japan Earthquake -a report from the CHART-2 Study- Eur Heart J QCCO. 3:224-233,2017.PDF
  8. Aoki T, Shimokawa H. Earthquake and hypertension-from acute to chronic phase after the Great East Japan Earthquake. J Xiangya Med. 2:9,2017.PDF
  9. Cui Y, Hao K, Takahashi J, Miyata S, Shindo T, Nishimiya K, Kikuchi Y, Tsuburaya R, Matsumoto Y, Ito K, Sakata Y, Shimokawa H. Age-specific trends in the incidence and in-hospital mortality of acute myocardial infarction over 30 years in Japan - Report from the Miyagi AMI Registry Study- Circ J. 81:520-528,2017. (IF=3.544)PDF
  10. Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Takeo Onose T, Abe R, Oikawa T, Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa S; the CHART-2 Investigators. Characterization of heart failure patients with mid-range left ventricular ejection fraction -A report from the CHART-2 Study- Eur J Heart Fail. DOI: 10.1002/ejhf.807. (IF=6.968)
  11. Miyata S, Sakata Y, Miura M, Yamauchi T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Sato M, Nochioka K, Shiroto T, Takahashi J, Shimokawa H; the CHART-2 investigators. Long-term prognostic impact of the Great East Japan Earthquake in patients with cardiovascular disease -Report from the CHART-2 Study- J Cardiol. 70:286-296,2017. (IF=2.732)PDF
  12. Nochioka K, Biering-Sorensen T, Hansen KW, Sorensen R, Pedersen S, Jorgensen PG, Allan Iversen A, Shimokawa H, Jeger R, Kaiser C, Pfisterer M, Galatius S, on behalf of the BASKET-PROVE Investigators. Long-term outcome in patients with rheumatologic disorders after percutaneous coronary intervention: A BASKET-PROVE Substudy. Eur Heart J. Acute Cardiovasc Care. 6:778-786,2017.PubMed
  13. Ohtsuki T, Satoh K, Omura J, Kikuchi N, Satoh T, Kurosawa R, Nogi M, Sunamura S, Yaoita N, Aoki T, Tatebe S, Sugimura K, Takahashi J, Miyata S, Shimokawa H. Prognostic impacts of plasma levels of cyclophilin A in patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 37:685-693,2017. (IF=6.607)PDF
  14. Beltrame J, Crea F, Kaski JC, Ogawa H, Ong P, Sechtem U, Shimokawa H, Merz CNB; COVADIS Group. International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. doi:10.1093/eurheartj/ehv351.PDF
  15. Yamauchi T, Sakata Y, Miura M, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Nochioka K, Shiroto T, Takahashi J, Miyata S, Shimokawa H; the CHART-2 investigators. Prognostic impact of atrial fibrillation and new risk score of its onset in patients at high risk of heart failure -A report from the CHART-2 Study- Circ J. 81:185-194,2017. (IF=3.544)PDF
2016年
  1. Beltrame JF, Crea F, Kaski JC, Ogawa H, Ong P, Sechtem U, Shimokawa H, Merz CNB, the COVADIS Group. The who, what, why, when, how and where of vasospastic angina. Circ J. 80:289-298,2016.PDF
  2. Ikeda T, Atarashi H, Inoue H, Uchiyama S, Kitazono T, Yamashita T, Shimizu W, Kamouchi M, Kaikita K, Fukuda K, Origasa H, Sakuma I, Saku K, Okumura Y, Nakamura Y, Morimoto H, Matsumoto N, Tsuchida A, Ako J, Sugishita N, Shimizu S, Shimokawa H, the EXPAND Investigators. The EXPAND Study: study design and baseline patient characteristics -Evaluation of effectiveness and safety of Xa inhibitor, rivaroxaban for the prevention of stroke and systemic embolism in a nationwide cohort of Japanese patients diagnosed as non-valvular atrial fibrillation-. Tohoku J Exp Med. 240:259-268,2016.PDF
  3. Konishi M, Ishida J, Springer J, von Haehling S, Akashi YJ, Shimokawa H, Anker SD. Heart failure epidemiology and novel treatments in Japan: facts and numbers. (Editorial) ESC Heart Failure. 3:145-151,2016. PDF
  4. Miura M, Sakata Y, Miyata S, Shiba N, Takahashi J, Nochioka K, Takada T, Saga C, Shinozaki T, Sugi M, Nakagawa M, Sekiguchi N, Komaru T, Kato A, Fukuchi M, Nozaki E, Hiramoto T, Inoue K, Goto T, Ohe M, Tamaki K, Ibayashi S, Ishide N, Maruyama Y, Tsuji I, Shimokawa H; SUPPORT Trial Investigators. Influence of left ventricular ejection fraction on the effects of supplemental use of angiotensin receptor blocker olmesartan in hypertensive patients with heart failure. Circ J. 80:2155-2164,2016.PDF
  5. Miura M, Sugimura K, Sakata Y, Miyata S, Tadaki S, Yamauchi T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Shimokawa H ; CHART-2 Investigators. Prognostic impact of loop diuretics in patients with chronic heart failure -Effects of addition of renin-angiotensin-aldosterone system inhibitors and β-blockers. Circ J. 80:1396-1403,2016.PDF
  6. Sato H, Miura M, Yaoita N, Yamamoto S, Tatebe S, Aoki T, Satoh K, Ota H, Takase K, Sugimura K, Shimokawa H. Pulmonary Arterial Hypertension Associated with Congenital Portosystemic Shunts Treated with Transcatheter Embolization and Pulmonary Vasodilators. Intern Med. 55:2429-2432,2016.PubMed
  7. Suzuki H, Sugimura K, Tatebe S, Aoki T, Shimokawa H. Chronic thromboembolic pulmonary hypertension and schizophrenia. Int J Cardiol. 207:363-364,2016.PDF
  8. Tadaki S, Sakata Y, Miura Y, Miyata S, Asakura M, Shimada K, Yamamoto T, Fukumoto Y, Kadokami T, Yasuda S, Miura T, Ando S, Yano M, Kitakaze M, Daida H, Shimokawa H. Prognostic impacts of metabolic syndrome in patients with chronic heart failure -A multicenter prospective cohort study- Circ J. 80:677-688,2016.PDF
  9. Tsuburaya R, Takahashi J, Nakamura A, Nozaki E, Sugi M, Yamamoto Y, Hiramoto T, Horiguchi S, Inoue K, Goto T, Kato A, Shinozaki T, Ishida E, Miyata S, Yasuda S, Shimokawa H; the NOVEL Investigators. Beneficial effects of long-acting nifedipine on coronary vasomotion abnormalities after drug-eluting stent implantation. -The NOVEL Study- Eur Heart J. 37:2713-2721,2016.PDF
  10. Tsutsui H, Momomura S, Yamashina A, Ogawa H, Shimokawa H, Kihara Y, Saito Y, Hagiwara N, Ito H, Ako J, Inomata T, Tanaka T, Kawasaki Y, on behalf of the study investigators. Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure -A randomized, double-blind, placebo-controlled phase II study- Circ J. 80:668-676,2016.PDF
  11. Yoshida M, Watanabe R, Ishii T, Machiyama T, Akita K, Fujita Y, Shirota Y, Sugimura K, Fujii H, Shimokawa H, Harigae H. Retrospective analysis of 95 patients with large vessel vasculitis: a single center experience. Int J Rheumatic Dis. 19:87-94,2016.PubMed
2015年
  1. Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, Ushigome R, Yamauchi T, Sato K, Onose T, Tsuji K, Abe R, Takahashi J, Shimokawa H, the CHART-2 investigators. Prognostic impact of diabetes mellitus in chronic heart failure according to presence of ischemic heart disease. -With special reference to nephropathy- Circ J. 79:1764-1772,2015.PDF
  2. Nochioka K, Sakata Y, Miyata S, Miura M, Takada T, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Shimokawa H. Prognostic impact of statin use in patients with heart failure with preserved ejection fraction -A report from the CHART-2 Study- Circ J. 79:574-582,2015.PDF
  3. Onose T, Nochioka K, Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Sato K, Tsuji K, Abe R, Miyata S, Takahashi J, Shimokawa H. Predictors and prognostic impact of post-traumatic stress disorder after the Great East Japan Earthquake in patients with cardiovascular disease -- Report from the CHART-2 Study -- Circ J. 79:664-667,2015.PDF
  4. Sakata Y, Shiba N, Takahashi J, Miyata S, Nochioka K, Miura M, Takada T, Saga C, Shinozaki T, Sugi M, Nakagawa M, Sekiguchi N, Komaru T, Kato A, Fukuchi M, Nozaki E, Hiramoto T, Inoue K, Goto T, Ohe M, Tamaki K, Ibayashi S, Ishide N, Maruyama Y, Tsuji I, Shimokawa H, on behalf of the SUPPORT Trial Investigators. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure. -The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) Trial- Eur Heart J. 36:915-923,2015. PDF
  5. Satake H, Sugimura K, Fukumoto Y, Fukuda K, Nakano M, Kondo M, Fukui S, Ogawa H, Shinozaki T, Shimokawa H. Effects of respiratory therapy on the prognosis of chronic heart failure patients complicated with sleep-disordered breathing -A pilot efficacy trial- Circ J. 80:130-138,2015.PubMed
  6. Satake H, Fukuda K, Sakata Y, Miyata S, Nakano M, Kondo M, Hasebe Y, Segawa M, Shimokawa H, the CHART-2 Investigators. Current status of primary prevention of sudden cardiac death with implantable cardioverter defibrillator in patients with chronic heart failure. -A report from the CHART-2 Study- Circ J. 79:381-390,2015.PDF
  7. Satoh K, Shimokawa H. Cyclophilin A: Novel biomarker for oxidative stress and cardiovascular diseases. In: Preedy VR, Patel VB (eds), General Methods in Biomarker Research and Their Applications, pp. 405-438, Springer Reference, London, 2015.
  8. Sato K, Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Onode T, Tsuji K, Abe R, Nochioka K, Takahashi J, Miyata S, Shimokawa H, the CHART-2 investigators. Comprehensive risk stratefification of Japanese patients with aortic stenosis. -A proposal of a new risk score from the CHART-2 Study- Circ J. 79:1631-1638,2015.PDF
  9. Shimokawa H, Miura M, Nochioka K, Sakata Y. Heart failure as a general pandemic in Asia. Eur J Heart Fail. 17:884-892,2015PubMed
  10. Takahashi J, Shimokawa H. Earthquake, cardiovascular diseases and implications for public health. In Watson RR, Tabor JA, Ehiri JE, Preedy (eds.), Handbook of Public Health in Natural Disasters, pp.309-333, Wageningen Academic Publishers, The Netherlands, 2015.
  11. Takahashi J, Nihei T, Takagi Y, Miyata S, Odaka Y, Tsunoda R, Seki A, Sumiyoshi T, Matsui M, Goto T, Tanabe Y, Sueda S, Momomura S, Yasuda S, Ogawa H, Shimokawa H, on behalf of the Japanese Coronary Spasm Association. Prognostic impact of chronic nitrate therapy in patients with vasospastic angina -Multicenter registry study of the Japanese Coronary Spasm Association- Eur Heart J. 36:228-237,2015.PDF
  12. Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Yamauchi T, Sato K, Onose T, Tsuji K, Abe R, Takahashi J, Shimokawa H; the CHART-2 Investigators, Improved long-term prognosis of patients with dilated cardiomyopathy with implementation of evidenced-based medications. -A report from the CHART Studies- Circ J. 79:1332-1341,2015.PDF
  13. Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Yamauchi T, Sato K, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Takahashi J, Shimokawa H, the CHART-2 Investigators. Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in Japan -A report from the CHART Studies- Circ J. 79:2396-2407,2015.PDF
  14. Yamauchi T, Sakata Y, Takada T, Nochioka K, Miura M, Tadaki S, Ushigome R, Sato K, Onose T, Tsuji K, Abe R, Takahashi J, Miyata S, Shimokawa H. Prognostic impacts of anemia in patients with chronic heart failure with a special reference to clinical background -A report from the CHART-2 Study- Circ J. 79:1984-1993,2015PubMed
2014年
  1. Hao K, Takahashi J, Aoki T, Miyata S, Ito K, Sakata Y, Shimokawa H. Factors influencing the occurrence of cardiopulmonary arrest in the Great East Japan Earthquake Disaster. Intn'l J Cardiol. 177:569-572,2014.PubMed
  2. Hao K, Takahashi J, Ito K, Miyata S, Sakata Y, Nihei T, Tsuburaya R, Shiroto T, Ito Y, Matsumoto Y, Nakayama M, Yasuda S, Shimokawa H. Emergency care of acute myocardial infarction and the Great East Japan Earthquake Disaster -Report From the Miyagi AMI Registry Study- Circ J. 78:634-643,2014.PDF
  3. Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Shimokawa H. Prognostic impact of subclinical microalbuminuria in patients with chronic heart failure -A report from the CHART-2 Study- Circ J. 78:2890-2898,2014.PDF
  4. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Siswanto BB, Sliwa K, Filippatos G. Heart failure: preventing disease and death worldwide. ESC Heart Failure. 1:4-25,2014.PDF
  5. Sakata Y, Miyata S, Nochioka K, Miura M, Takada T, Tadaki S, Takahashi J, Shimokawa H. Gender differences in clinical characteristics, treatment and long-term outcome in patients with stage C/D heart failure in Japan -A report from the CHART-2 Study- Circ J. 78:428-435,2014.PDF
  6. Satoh K, Shimokawa H. High-sensitivity C-reactive protein: Still need for next-generation biomarkers for remote future cardiovascular events. Eur Heart J. 35:1776-1778,2014. (Editorial)PDF
  7. Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Tadaki S, Shimokawa H, on behalf of the CHART-2 Investigators. Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction. -A report from the CHART-2 Study- Eur J Heart Fail. 16:309-316,2014.PDF
2013年
  1. Aoki T, Takahashi J, Fukumoto Y, Yasuda S, Ito K, Miyata S, Shinozaki T, Inoue K, Yagi T, Komaru T, Katahira Y, Obata A, Hiramoto T, Sukegawa H, Ogata K, Shimokawa H. Effect of the Great East Japan Earthquake Disaster on cardiovascular diseases -A report from the 10 hospitals in the Disaster area- Circ J. 77:490-493,2013.PDF
  2. Fukumoto Y, Yamada N, Matsubara H, Mizoguchi M, Uchino K, Yao A, Kihara Y, Kawano M, Watanabe H, Takeda Y, Adachi T, Osanai S, Tanabe N, Inoue T, Kubo A, Ota Y, Fukuda K, Nakano T, Shimokawa H. Double-blind, placebo-controlled clinical trial with a Rho-kinase inhibitor in pulmonary arterial hypertension -A pilot efficacy trial- Circ J. 77:2619-2625,2013.PDF
  3. Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, Takahashi J, Shiba N, Shimokawa H, on behalf of the CHART-2 Investigators. Usefulness of combined risk stratification with Heart rate and systolic blood pressure in the management of chronic heart failure -A report from the CHART-2 Study- Circ J. 77:2954-2962,2013.PDF
  4. Miura M, Sakata Y, Nochioka K, Takahashi J, Takada T, Miyata S, Hiramoto T, Inoue K, Tamaki K, Shiba N, Shimokawa H. Prognostic impact of blood urea nitrogen changes during hospitalization in patients with acute heart failure syndrome. Circ J. 77:1221-1228,2013.PDF
  5. Nochioka K, Sakata Y, Takahashi J, Miyata S, Miura M, Takada T, Fukumoto Y, Shiba N, Shimokawa H. Prognostic impact of nutritional status in asymptomatic patients with cardiac diseases: a report from the CHART-2 Study. Circ J. 77:2318-2326,2013.PDF
  6. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J. 77:2209-2217,2013.PDF
  7. Sakata Y, Shimokawa H. Saturated fatty acid intake and cardiovascular risk. Eur Heart J. 34:1178-1180,2013.PDF
  8. Sakata Y, Nochioka K, Miura M, Takada T, Tadaki S, Miyata S, Shiba N, Shimokawa H, for the SUPPORT Trial Investigators. Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial-Rationale and design. J Cardiol. 62:31-36,2013.PDF
  9. Satoh K, Fukumoto Y, Sugimura K, Miura Y, Aoki T, Nochioka K, Tatebe S, Miyamichi-Yamamoto S, Shimizu T, Osaki S, Takagi Y, Tsuburaya R, Ito Y, Matsumoto Y, Nakayama M, Takeda M, Takahashi J, Ito K, Yasuda S, Shimokawa H. Plasma cyclophilin A is a novel biomarker for coronary artery disease. Circ J. 77:447-455,2013.PDF
  10. Takagi Y, Takahashi J, Yasuda S, Miyata S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Goto T, Tanabe Y, Sueda S, Sato T, Ogawa S, Kubo N, Momomura S, Ogawa H, Shimokawa H, on Behalf of the Japanese Coronary Spasm Association. Prognostic stratification of patients with vasospastic angina - A comprehensive clinical risk score developed by the Japanese Coronary Spasm Association - J Am Coll Cardiol. 62:1144-1153,2013.PDF
  11. Takagi Y, Yasuda S, Takahashi J, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Goto T, Tanabe Y, Sueda S, Sato T, Ogawa S, Kubo N, Momomura S, Ogawa H, Shimokawa H. Clinical implications of provocation tests for coronary artery spasm: safety, arrhythmic complications and prognostic impact -Multicenter registry study of the Japanese Coronary Spasm Association- Eur Heart J. 34:258-267,2013.PDF
2012年
  1. Aoki T, Fukumoto Y, Yasuda S, Sakata Y, Ito K, Takahashi J, Miyata S, Tsuji I, Shimokawa H. The Great East Japan Earthquake Disaster and cardiovascular diseases. Eur Heart J. 33:2796-2803,2012.PDF
  2. Hao K, Yasuda S, Takii T, Ito Y, Takahashi J, Ito K, Nakayama M, Shiba N, Fukumoto Y, Shimokawa H. Urbanization, life-style changes and incidence and in-hospital mortality from acute myocardial infarction in Japan -Report from the MIYAGI-AMI Registry- Circ J. 76:1136-1144,2012.PDF
  3. Kromhout D, Yasuda S, Geleijnse JM, Shimokawa H. Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work? Eur Heart J. 33:436-443,2012.PDF
  4. Miura M, Shiba N, Nochioka K, Takada T, Takahashi J, Kohno H, Shimokawa H, on behalf of the CHART-2 Investigators. Urinary albumin excretion in heart failure with preserved ejection fraction: an interim analysis of the CHART 2 study. Eur J Heart Fail. 14:367-376,2012.PDF
  5. Nakano M, Kondo M, Wakayama Y, Kawana A, Hasebe Y, Shafee MA, Fukuda K, Shimokawa H. Increased Incidence of tachyarrhythmias and heart failure hospitalization in patients implanted with cardiac devices after the Great East Japan Earthquake Disaster. Circ J. 76:1283-1285,2012.PDF
  6. Nihei T, Takahashi J, Kikuchi Y, Takagi Y, Hao K, Tsuburaya R, Shiroto T, Ito Y, Matsumoto Y, Nakayama M, Ito K, Yasuda S, Shimokawa H. Enhanced Rho-kinase activity in patients with vasospastic angina after the Great East Japan Earthquake. Circ J. 76:2892-2894,2012.PDF
  7. Shiba N, Shimokawa H. Prospective care of heart failure in Japan: Lessons from CHART Studies. EPMA. 2:425-438,2012.PDF
2011年
  1. Shiba N, Nochioka K, Miura M, Kouno H, Shimokawa H. Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan--first report from the CHART-2 study. Circ J. 75:823-833,2011.PDF
  2. Shiba N, Shimokawa H. Chronic kidney disease and heart failure--Bidirectional close link and common therapeutic goal. J Cardiol. 57:8-17,2011. (Review)PubMed
2010年
  1. Nochioka K, Shiba N, Kohno H, Miura M, Shimokawa H. Both high and low body mass indexes are prognostic risks in japanese patients with chronic heart failure - implications from the CHART Study - J Card Fail. 16:880-887,2010.PubMed
  2. Takii T, Yasuda S, Takahashi J, Ito K, Shiba N, Shirato K, Shimokawa H; MIYAGI-AMI Study Investigators. Trends in acute myocardial infarction incidence and mortality over 30 years in Japan: report from the MIYAGI-AMI Registry Study. Circ J. 74:93-100,2010.PubMed
2008年
  1. Shiba N, Matsuki M, Takahashi J, Tada T, Watanabe J, Shimokawa H. Prognostic importance of chronic kidney disease in Japanese patients with chronic heart failure. Circ J. 72:173-178,2008.PubMed
  2. Shiba N, Shimokawa H. Chronic heart failure in Japan: Implications of the CHART studies. Vasc Health Risk Manag. 4:103-113,2008.PubMed
2007年
  1. Shirato K, Shiba N, Shimokawa H. Chronic Heart Failure Analysis and Registry in the Tohoku District: the CHART study. Nippon Rinsho. 65 Suppl 4:74-78,2007.Apr 28.PubMed
  2. Tada T, Shiba N, Watanabe J, Matsuki M, Kagaya Y, Shinozaki T, Shirato K, Shimokawa H. Prognostic value of anemia in predicting sudden death of patients with diastolic heart failure. Int J Cardiol. 128:419-421,2007.PubMed
2006年
  1. Watanabe J, Shinozaki T, Shiba N, Fukahori K, Koseki Y, Karibe A, Sakuma M, Miura M, Kagaya Y, Shirato K. Accumulation of risk markers predicts the incidence of sudden death in patients with chronic heart failure. Eur J Heart Fail. 8:237-242,2006.PubMed
2005年
  1. Shiba N, Watanabe J, Shinozaki T, Koseki Y, Sakuma M, Kagaya Y, Shirato K. Poor prognosis of Japanese patients with chronic heart failure following myocardial infarction--comparison with nonischemic cardiomyopathy. Circ J. 69:143-149,2005.PubMed
  2. Watanabe J, Shiba N, Shinozaki T, Koseki Y, Karibe A, Komaru T, Miura M, Fukuchi M, Fukahori K, Sakuma M, Kagaya Y, Shirato K. Prognostic value of plasma brain natriuretic peptide combined with left ventricular dimensions in predicting sudden death of patients with chronic heart failure. J Card Fail. 11:50-55,2005.PubMed
2004年
  1. Shiba N, Watanabe J, Shinozaki T, Koseki Y, Sakuma M, Kagaya Y, Shirato K; CHART Investigators. Analysis of chronic heart failure registry in the Tohoku district: third year follow-up. Circ J. 68:427-434,2004.PubMed

(文責:柴信行)

このページのTOPへ